AR076413A1 - Metodo para atenuar mycoplasma bovis y su vacuna - Google Patents

Metodo para atenuar mycoplasma bovis y su vacuna

Info

Publication number
AR076413A1
AR076413A1 ARP100101382A ARP100101382A AR076413A1 AR 076413 A1 AR076413 A1 AR 076413A1 AR P100101382 A ARP100101382 A AR P100101382A AR P100101382 A ARP100101382 A AR P100101382A AR 076413 A1 AR076413 A1 AR 076413A1
Authority
AR
Argentina
Prior art keywords
atenuating
vaccine
bovis
mycoplasma bovis
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP100101382A
Other languages
English (en)
Inventor
Michael Beck
Jeffrey KNITTEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Original Assignee
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica de C V SA, Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica de C V SA
Publication of AR076413A1 publication Critical patent/AR076413A1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cepas bacterianas de M. bovis atenuadas sometidas a pases al menos 110 veces. Además, composiciones inmunogénicas que comprenden bacterias vivas de cualquiera de esta cepas bacterianas de M. bovis atenuadas, su fabricacion y uso para el tratamiento y profilaxis de infecciones de M. bovis y combinaciones con otras vacunas o medicamentos veterinarios.
ARP100101382A 2009-04-24 2010-04-23 Metodo para atenuar mycoplasma bovis y su vacuna Pending AR076413A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17254309P 2009-04-24 2009-04-24

Publications (1)

Publication Number Publication Date
AR076413A1 true AR076413A1 (es) 2011-06-08

Family

ID=42331013

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101382A Pending AR076413A1 (es) 2009-04-24 2010-04-23 Metodo para atenuar mycoplasma bovis y su vacuna

Country Status (20)

Country Link
US (1) US9339533B2 (es)
EP (1) EP2421556B1 (es)
JP (1) JP5793808B2 (es)
KR (1) KR101880888B1 (es)
CN (1) CN102458461B (es)
AR (1) AR076413A1 (es)
AU (1) AU2010238689B2 (es)
BR (1) BRPI1013836B1 (es)
CA (1) CA2758733C (es)
CL (1) CL2011002639A1 (es)
CO (1) CO6460761A2 (es)
DK (1) DK2421556T3 (es)
ES (1) ES2630209T3 (es)
HU (1) HUE033618T2 (es)
MX (1) MX342443B (es)
NZ (1) NZ595914A (es)
PL (1) PL2421556T3 (es)
SG (2) SG175323A1 (es)
UY (1) UY32570A (es)
WO (1) WO2010124154A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030619A2 (en) * 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
EP2362780B1 (en) 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
WO2011056175A1 (en) * 2009-11-06 2011-05-12 Intervet International B.V. Methods of immunizing pregnant heifers at three months of gestation
CN102294026A (zh) * 2010-11-17 2011-12-28 赤峰博恩药业有限公司 奶牛链球菌乳房炎灭活疫苗及其制备方法
US9175049B2 (en) * 2012-10-24 2015-11-03 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
JP6370807B2 (ja) 2013-12-18 2018-08-08 旭化成株式会社 乳汁中のストレプトコッカス属の菌を検出する方法
CN103800901B (zh) * 2014-01-27 2015-12-09 内蒙古华希生物科技有限公司 链球菌以及将其灭活得到的奶牛乳房炎疫苗
CN108135989B (zh) 2015-08-14 2022-08-09 硕腾服务有限责任公司 牛支原体组合物
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
CN107815439A (zh) * 2016-09-14 2018-03-20 华威特（江苏）生物制药有限公司 牛传染性鼻气管炎病毒jsm株及其应用
CN107759674B (zh) * 2017-09-26 2021-12-28 中国农业科学院哈尔滨兽医研究所 一种牛支原体免疫相关性蛋白、含有该蛋白的检测试剂盒及其在牛支原体抗体检测中的用途
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN109847060A (zh) * 2019-04-19 2019-06-07 黑龙江八一农垦大学 牛多杀性巴氏杆菌病、溶血性曼氏杆菌病二联灭活疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111733094B (zh) * 2020-05-29 2022-09-09 内蒙古民族大学 一种牛源蜡样芽孢杆菌及其应用
AR124849A1 (es) 2021-02-11 2023-05-10 Intervet Int Bv Vacuna para mycoplasma bovis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8296498A (en) 1997-07-10 1999-02-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
BR0015398A (pt) * 1999-11-08 2002-06-25 Biomune Vacinas para mycoplasma bovis e processos de uso
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
BR0211049A (pt) * 2001-07-02 2004-07-20 Pfizer Prod Inc Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
KR20040031015A (ko) 2001-08-28 2004-04-09 화이자 프로덕츠 인크. 마이코플라즈마 보비스 시험감염 모델, 엠. 보비스 투여방법 및 폐렴성 폐 병변 유도 방법
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) * 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
WO2008030619A2 (en) 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
CN100419073C (zh) * 2006-09-28 2008-09-17 中国兽医药品监察所 猪喘气病活疫苗及其生产方法
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
CL2008002675A1 (es) * 2007-09-11 2008-11-07 Wyeth Corp Bacteria de mycoplasma gallisepticum atenuada; composicion de vacuna que la comprende; método de vacunación; y método de identificación de clones de mycoplasma gallisepticum atenuados.
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
CA2729080C (en) 2008-07-03 2018-09-11 Ricardo Rosenbusch Cattle vaccines
EP2362780B1 (en) 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
CO6460761A2 (es) 2012-06-15
WO2010124154A1 (en) 2010-10-28
AU2010238689B2 (en) 2017-01-19
CL2011002639A1 (es) 2012-07-20
CA2758733C (en) 2019-12-24
AU2010238689A1 (en) 2011-11-03
JP2012524548A (ja) 2012-10-18
EP2421556A1 (en) 2012-02-29
SG10201401784WA (en) 2014-08-28
SG175323A1 (en) 2011-11-28
HUE033618T2 (en) 2017-12-28
EP2421556B1 (en) 2017-04-05
BRPI1013836B1 (pt) 2020-04-14
KR20120109992A (ko) 2012-10-09
KR101880888B1 (ko) 2018-07-23
CN102458461B (zh) 2017-03-08
DK2421556T3 (en) 2017-07-10
CA2758733A1 (en) 2010-10-28
CN102458461A (zh) 2012-05-16
UY32570A (es) 2010-11-30
US9339533B2 (en) 2016-05-17
MX2011010976A (es) 2011-11-18
NZ595914A (en) 2014-09-26
ES2630209T3 (es) 2017-08-18
PL2421556T3 (pl) 2017-09-29
JP5793808B2 (ja) 2015-10-14
US20100272759A1 (en) 2010-10-28
MX342443B (es) 2016-09-29

Similar Documents

Publication Publication Date Title
AR076413A1 (es) Metodo para atenuar mycoplasma bovis y su vacuna
UY31437A1 (es) Vacuna de mycoplasma bovis y métodos de uso de la misma
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
CO6880050A2 (es) Composiciones y metodos para controlar la fusariosis
BR112016006589A2 (pt) composição, e composição de vacina
CL2016002992A1 (es) Combinación, composición y método de administración de la combinación o composición a animales
MX2016009898A (es) Tratamientos para acne resistente.
AR072435A1 (es) Composicion nutricional para lactantes nacidos por cesarea
CL2011002852A1 (es) Uso de bacterias del acido lactico probioticas por un tratamiento con calor para la preparacion de composiciones para prevenir o tratar inmunodeficiencias causadas por infecciones bacterianas, virales, fungicas y/o parasitarias.
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
BR112018070331A2 (pt) composições produzidas por micro-organismos tendo atividade estimulatória em plantas
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
UA98506C2 (en) Attenuated mycoplasma gallisepticum strains
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
CL2011001284A1 (es) Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab.
PH12016500946A1 (en) Composition for preventing and curing mycoplasma infection
MX2017016401A (es) Composiciones inmunogenas.
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
BR112022005345A2 (pt) Composições imunogênicas
GB2515222A (en) Use of flagellin as a vaccine

Legal Events

Date Code Title Description
FG Grant, registration